Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Halozyme Therapeutics, Inc. - Common Stock (NQ: HALO )

58.29 -0.32 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. 
Via Chartmill
The 3 Best Biotech Stocks to Buy in May 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Expert Ratings For Halozyme Therapeutics
Via Benzinga
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:HALO is not too expensive for the growth it is showing.
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
Sarepta Therapeutics Stock Shows Improved Technical Strength
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results. 
Via Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. 
Via Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
Via Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. 
Via Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
Halozyme Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Preview: Halozyme Therapeutics
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S. 
Via Benzinga
NASDAQ:HALO, an undervalued stock with good fundamentals.
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued. 
Via Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.